lexi
IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 3507 
Small font sizeDefault font sizeIncrease font size
Read this article

 


    Article Cited by others

EDUCATIONAL FORUM

The Tamiflu fiasco and lessons learnt

Gupta Yogendra Kumar, Meenu Meenakshi, Mohan Prafull

Year : 2015| Volume: 47| Issue : 1 | Page no: 11-16

   This article has been cited by
 
1 Targeting cancer-associated glycans as a therapeutic strategy in leukemia
Ashraf Abdullah Saad
All Life. 2022; 15(1): 378
[Pubmed]  [Google Scholar] [DOI]
2 Therapeutic Effect of Neuraminidase-1–Selective Inhibition in Mouse Models of Bleomycin-Induced Pulmonary Inflammation and Fibrosis
Irina G. Luzina, Erik P. Lillehoj, Virginia Lockatell, Sang W. Hyun, Katerina N. Lugkey, Akihiro Imamura, Hideharu Ishida, Christopher W. Cairo, Sergei P. Atamas, Simeon E. Goldblum
Journal of Pharmacology and Experimental Therapeutics. 2021; 376(1): 136
[Pubmed]  [Google Scholar] [DOI]
3 A Comparative Analysis on Four European Countries COVID-19 Response: Focused on the 1st Wave
Eunsol Song, Juhyun Moon, Ji-Hye Byun, Jina Jun, Nam-soon Kim
Health Insurance Review & Assessment Service Research. 2021; 1(1): 50
[Pubmed]  [Google Scholar] [DOI]
4 Ensuring Prevention Science Research is Synthesis-Ready for Immediate and Lasting Scientific Impact
Emily A. Hennessy, Rebecca L. Acabchuk, Pieter A. Arnold, Adam G. Dunn, Yong Zhi Foo, Blair T. Johnson, Sonya R. Geange, Neal R. Haddaway, Shinichi Nakagawa, Witness Mapanga, Kerrie Mengersen, Matthew J. Page, Alfredo Sánchez-Tójar, Vivian Welch, Luke A. McGuinness
Prevention Science. 2021;
[Pubmed]  [Google Scholar] [DOI]
5 Perspective sur la responsabilité de l’industrie pharmaceutique dans la promotion de la recherche pédiatrique et dans l’accès aux médicaments essentiels
Neyla Dahane, Béatrice Godard
Global Health Promotion. 2021; 28(3): 78
[Pubmed]  [Google Scholar] [DOI]
6 Method Development and Validation for the Trace Level Quantification of Genotoxic Impurity Oseltamivir Phosphate Related Compound-a in Oseltamivir Phosphate Using LC-MS
Pikkili Viswanath, Doddipalli Venkata Ramana Reddy, Nagaraju Chamarthi
Oriental Journal Of Chemistry. 2021; 37(5): 1192
[Pubmed]  [Google Scholar] [DOI]
7 Outcomes of early oseltamivir treatment for hospitalized adult patients with community-acquired influenza pneumonia
Narongdet Kositpantawong, Smonrapat Surasombatpattana, Pisud Siripaitoon, Siripen Kanchanasuwan, Thanaporn Hortiwakul, Boonsri Charernmak, Ozioma Forstinus Nwabor, Sarunyou Chusri, Robert Jeenchen Chen
PLOS ONE. 2021; 16(12): e0261411
[Pubmed]  [Google Scholar] [DOI]
8 O “kit-covid” e o Programa Farmácia Popular do Brasil
Cláudia Du Bocage Santos-Pinto, Elaine Silva Miranda, Claudia Garcia Serpa Osorio-de-Castro
Cadernos de Saúde Pública. 2021; 37(2)
[Pubmed]  [Google Scholar] [DOI]
9 Potential Role of Endonuclease Inhibition and Other Targets in the Treatment of Influenza
Doreen Szollosi, Ashley Bill
Current Drug Targets. 2020; 21(2): 202
[Pubmed]  [Google Scholar] [DOI]
10 Association study of genetic polymorphisms in proteins involved in oseltamivir transport, metabolism, and interactions with adverse reactions in Mexican patients with acute respiratory diseases
Mario Bermúdez de León, Rafael B. R. León-Cachón, Beatriz Silva-Ramírez, Rosa Nelly González-Ríos, Brenda Escobedo-Guajardo, Roberto Leyva-Parra, Benjamín Tovar-Cisneros, Everardo González-González, Abdiel Alvarado-Díaz, Ofelia Vázquez-Monsiváis, Viviana Mata-Tijerina, Lorena Puente-Lugo, Erick Álvarez-Galván, María José Currás-Tuala, Miguel Aguado-Barrera, Fabiola Castorena-Torres, Juan Manuel Alcocer-González, Guillermo Elizondo, Ana María Salinas-Martínez
The Pharmacogenomics Journal. 2020; 20(4): 613
[Pubmed]  [Google Scholar] [DOI]
11 Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
Nayoung Han, Jung Mi Oh, In-Wha Kim
Scientific Reports. 2020; 10(1)
[Pubmed]  [Google Scholar] [DOI]
12 Radical Approaches During Unusual Circumstances: Intellectual Property Regulation and the COVID-19 Dilemma
Mohammed El Said
Development. 2020; 63(2-4): 209
[Pubmed]  [Google Scholar] [DOI]
13 Covid-19: What now for remdesivir?
Jeremy Hsu
BMJ. 2020; : m4457
[Pubmed]  [Google Scholar] [DOI]

 

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow